Learning and confirming with preclinical studies: Modeling and simulation in the discovery of GDC-0917, an inhibitor of apoptosis proteins antagonist

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 2104-2113

  Wong, Harvey ^a   Gould, Stephen E ^a   Budha, Nageshwar ^a   Darbonne, Walter C ^a   Kadel III, Edward E ^a   La, Hank ^a   Alicke, Bruno ^a   Halladay, Jason S ^a   Erickson, Rebecca ^a   Portera, Chia ^a   Tolcher, Anthony W ^b   Infante, Jeffery R ^c   Mamounas, Michael ^a   Flygare, John A ^a   Hop, Cornelis E C A ^a   Fairbrother, Wayne J ^a  

^a GENENTECH INC   (United States)

^b South Texas Accelerated Research Therapeutics   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 CYCLOHEXYL 2 (2 (METHYLAMINO)PROPANAMIDO)ACETYL) N (2 (OXAZOL 2 YL) 4 PHENYLTHIAZOL 5 YL)PYRROLIDINE 2 CARBOXAMIDE; 1 [2 CYCLOHEXYL 2 (2 [METHYLAMINO]PROPANAMIDO)ACETYL]; CIAP 1; GDC 0152; GDC 0917; INHIBITOR OF APOPTOSIS PROTEIN; NEURONAL APOPTOSIS INHIBITORY PROTEIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SCREENING; DRUG TOLERABILITY; FEMALE; HAPLORHINI; HUMAN; KIDNEY CLEARANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SIMULATION; SINGLE DRUG DOSE;

ANIMALS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CELL LINE, TUMOR; DOGS; DRUG EVALUATION, PRECLINICAL; FEMALE; HALF-LIFE; HEPATOCYTES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MACACA FASCICULARIS; MALE; MICE; MICE, SCID; PROTEIN KINASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888591895     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053926     Document Type: Article

References (25)

1. Bonate PL and Howard D (2000) Prospective allometric scaling: does the emperor have clothes? J Clin Pharmacol 40:335-340.
2. Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071-1121.
3. Chien JY, Friedrich S, Heathman MA, de Alwis DP, and Sinha V (2005) Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation. AAPS J 7:E544-E559.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Flygare JA and Fairbrother WJ (2010) Small-molecule pan-IAP antagonists: a patent review. Expert Opin Ther Pat 20:251-267.
6. Flygare JA, Beresini M, Budha N, Chan H, Chan IT, Cheeti S, Cohen F, Deshayes K, Doerner K, and Eckhardt SG, et al. (2012) Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J Med Chem 55:4101-4113.
7. Gibaldi M and Perrier D (1982) Pharmacokinetics, 2nd ed, Marcel Dekker, New York.
8. Green S, Benedetti J, and Crowley J (2003) Clinical Trials in Oncology, 2nd ed, Chapman & Hall/CRC, Baton Rouge, FL.
9. Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti JM, Schepartz S, Kalyandrug S, Christian M, Arbuck S, and Hollingshead M, et al. (2001) Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84:1424-1431.
10. Kelland LR (2004) Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40:827-836.
11. Khojasteh SC, Wong H, and Hop CECA (2011) Drug Metabolism and Pharmacokinetics Quick Guide, Springer, New York.
12. Lin JH (1995) Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23:1008-1021.
13. Liu L, Di Paolo J, Barbosa J, Rong H, Reif K, and Wong H (2011) Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. J Pharmacol Exp Ther 338:154-163.
14. Mager DE, Wyska E, and Jusko WJ (2003) Diversity of mechanism-based pharmacodynamic models. Drug Metab Dispos 31:510-518.
15. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58.
16. Peterson JK and Houghton PJ (2004) Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur J Cancer 40:837-844.
17. Salphati L, Wong H, Belvin M, Edgar KA, Prior WW, Sampath D, and Wallin JJ (2010) Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug Metab Dispos 38:1436-1442.
18. Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61:275-291.
19. Varfolomeev E and Vucic D (2011) Inhibitor of apoptosis proteins: fascinating biology leads to attractive tumor therapeutic targets. Future Oncol 7:633-648.
20. Vucic D and Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13:5995-6000.
21. Wong H, Budha NR, West K, Blackwood E, Ware JA, Yu R, Darbonne WC, Gould SE, Steigerwalt R, and Erickson R, et al. (2012a) Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicol Sci 130:205-213.
22. Wong H, Choo EF, Alicke B, Ding X, La H, McNamara E, Theil FP, Tibbitts J, Friedman LS, and Hop CECA, et al. (2012b) Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 18:3846-3855.
23. Wong H, Vernillet L, Peterson A, Ware JA, Lee L, Martini J-F, Yu P, Li C, Del Rosario G, and Choo EF, et al. (2012c) Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res 18:3090-3099.
24. Yamazaki S, Vicini P, Shen Z, Zou HY, Lee J, Li Q, Christensen JG, Smith BJ, and Shetty B (2012) Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models. J Pharmacol Exp Ther 340:549-557.
25. Yue Q, Mulder T, Rudewicz PJ, Solon E, Budha N, Ware JA, Lyssikatos J, Hop CECA, Wong H, and Khojasteh SC (2013) Evaluation of metabolism and disposition of GDC-0152 in rats using 14C labeling strategy at two different positions: a novel formation of hippuric acid from 4-phenyl-5-amino-1,2,3- thiadiazole. Drug Metab Dispos 41:508-517.